Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
Inês Pires da SilvaKevin Y X WangJames S WilmottJeff HolstMatteo S CarlinoJohn J ParkCamelia QuekMatthew J WongchenkoYibing YanGraham J MannDouglas B JohnsonJennifer Leigh McQuadeRajat RaiRichard F KeffordHelen RizosRichard A ScolyerJean Yee Hwa YangGeorgina V LongAlexander M MenziesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
BRAF V600K melanomas appear to benefit less from BRAFi±MEKi than V600E, potentially due to less reliance on ERK pathway activation and greater use of alternative pathways. In contrast, these melanomas have higher mutational load and respond better to immunotherapy.